<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909610</url>
  </required_header>
  <id_info>
    <org_study_id>2006-1283</org_study_id>
    <nct_id>NCT00909610</nct_id>
  </id_info>
  <brief_title>Ursodiol Tablets 500 mg Under Fasting Conditions</brief_title>
  <official_title>A Single-Dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500 mg Tablets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to evaluate the comparative bioavailability between Ursodiol
      500 mg Tablets (test) and Urso Forte™ 500 mg Tablets (reference) after a single-dose in
      healthy subjects under fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria

      Statistical Methods: FDA bioequivalence statistical methods
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Concentration - for Total Ursodiol</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-72 - Area Under the Concentration-time Curve From Time Zero to 72 Hours - for Total Ursodiol</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Baseline Corrected Total Ursodiol</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-72 for Baseline Corrected Total Ursodiol</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Unconjugated Ursodiol</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-72 for Unconjugated Ursodiol</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Unconjugated Ursodiol - Baseline Corrected</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-72 for Unconjugated Ursodiol - Baseline Corrected</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ursodiol (test) First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ursodiol Tablets, 500 mg (test) dosed in first period followed by Urso Forte™ Tablets, 500 mg dosed in second period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Urso Forte™ (reference) First</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Urso Forte™ Tablets, 500 mg (reference) dosed in first period followed by Ursodiol Tablets, 500 mg (test) dosed in second period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodiol</intervention_name>
    <description>Ursodiol Tablets, 500 mg</description>
    <arm_group_label>Ursodiol (test) First</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urso Forte™</intervention_name>
    <description>Urso Forte™ Tablets, 500 mg</description>
    <arm_group_label>Urso Forte™ (reference) First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, non-smoking male and female subjects, 18 years of age or older.

          -  BMI ≥ 19 and ≤ 30.

          -  Negative for:

               1. HIV.

               2. Hepatitis B surface antigen and Hepatitis C antibody.

               3. Using drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine,
                  opiates, benzodiazepines and methadone).

               4. Urine cotinine test

               5. Serum HCG consistent with pregnancy (females only)

          -  No significant diseases or clinically significant findings in a physical examination.

          -  No clinically significant abnormal laboratory values.

          -  No clinically significant findings in vital signs measurements and a 12-lead
             electrocardiogram (ECG).

          -  Be informed of the nature of the study and given written consent prior to receiving
             any study procedure.

          -  Females who participate in this study are:

               1. unable to have children (e.g. post-menopausal, tubal ligation, hysterectomy) OR

               2. willing to remain abstinent [not engage in sexual intercourse] OR

               3. willing to use an effective method of double-barrier birth control (e.g. partner
                  using condom and female using diaphragm, contraceptive sponge, spermicide or IUD)

          -  Females who participate in this study are not pregnant and/or non-lactating.

        Exclusion Criteria:

          -  Known history or presence of any clinically significant medical condition.

          -  Known or suspected carcinoma.

          -  Known history or presence of:

               1. Hypersensitivity or idiosyncratic reaction to ursodiol and/or any other drug
                  substances with similar activity.

               2. Alcoholism within the last 12 months.

               3. Drug dependence and/or substance abuse.

               4. Use of tobacco or nicotine-containing products within the last 6 months.

          -  On a special diet within 4 weeks prior to drug administration (e.g. liquid, protein,
             raw food diet).

          -  Participated in another clinical trial or received and investigational product within
             30 days prior to drug administration.

          -  Donated up to 250 mL of blood within the previous 30 days OR Donated from 251 to 499
             mL of blood in the previous 45 days OR Donated more than 499 mL of blood in the
             previous 56 days (based on the Canadian Blood Services guideline for blood donation.

          -  Females taking oral or transdermal hormonal contraceptives within 14 days preceding
             period 1 dosing.

          -  Females having taken implanted or injected hormonal contraceptives within 6 months
             prior to period 1 dosing.

          -  Requirement of any non-topical medication (prescription and/or over-the-counter, with
             systemic absorption) on a routine basis.

          -  Difficulty fasting or consuming the standard meals.

          -  Do not tolerate venipuncture.

          -  Unable to read or sign the ICF.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xueyu (Eric) Chen, MD, PhD, FRCP(C)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharma Medica Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pharma Medica Research Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M1R 5A3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2009</study_first_submitted>
  <study_first_submitted_qc>May 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2009</study_first_posted>
  <results_first_submitted>June 12, 2009</results_first_submitted>
  <results_first_submitted_qc>June 12, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2009</results_first_posted>
  <last_update_submitted>August 14, 2009</last_update_submitted>
  <last_update_submitted_qc>August 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ursodiol (Test) First</title>
          <description>Ursodiol Tablets, 500 mg (test) dosed in first period followed by Urso Forte™ Tablets, 500 mg (reference) dosed in second period.</description>
        </group>
        <group group_id="P2">
          <title>Urso Forte™ (Reference) First</title>
          <description>Urso Forte™ Tablets, 500 mg (reference) dosed in first period followed by Ursodiol Tablets, 500 mg (test) dosed in second period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period: First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period: Washout of 28 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period: Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ursodiol</title>
          <description>Ursodiol Tablets, 500 mg (test) dosed in first period followed by Urso Forte™ Tablets, 500 mg (reference) dosed in second period.</description>
        </group>
        <group group_id="B2">
          <title>Urso Forte™</title>
          <description>Urso Forte™ Tablets, 500 mg (reference) dosed in first period followed by Ursodiol Tablets, 500 mg (test) dosed in second period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Concentration - for Total Ursodiol</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 72 hour period</time_frame>
        <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodiol Tablets, 500 mg (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Urso Forte™</title>
            <description>Urso Forte™ Tablets, 500 mg (reference) dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Concentration - for Total Ursodiol</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4946.800" spread="1919.778"/>
                    <measurement group_id="O2" value="5026.891" spread="2274.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of Variance (ANOVA) will be applied to log-transformed AUC's and Cmax parameters.</non_inferiority_desc>
            <param_type>Geometric Test/Ref Ratio x 100</param_type>
            <param_value>101</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.3</ci_lower_limit>
            <ci_upper_limit>111</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-72 - Area Under the Concentration-time Curve From Time Zero to 72 Hours - for Total Ursodiol</title>
        <description>Bioequivalence based on AUC0-72</description>
        <time_frame>Blood samples collected over 72 hour period</time_frame>
        <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodiol Tablets, 500 mg (test) dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Urso Forte™</title>
            <description>Urso Forte™ Tablets, 500 mg (reference) dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-72 - Area Under the Concentration-time Curve From Time Zero to 72 Hours - for Total Ursodiol</title>
          <description>Bioequivalence based on AUC0-72</description>
          <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76949.818" spread="29582.802"/>
                    <measurement group_id="O2" value="73342.048" spread="32482.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of Variance (ANOVA) will be applied to log-transformed AUC's and Cmax parameters.</non_inferiority_desc>
            <param_type>Ratio of the Geometric Mean</param_type>
            <param_value>106</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>101</ci_lower_limit>
            <ci_upper_limit>112</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Baseline Corrected Total Ursodiol</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 72 hour period</time_frame>
        <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodiol Tablets, 500 mg (test) dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Urso Forte™</title>
            <description>Urso Forte™ Tablets, 500 mg (reference) dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Baseline Corrected Total Ursodiol</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4864.646" spread="1910.294"/>
                    <measurement group_id="O2" value="4954.583" spread="2255.564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of Variance (ANOVA) will be applied to log-transformed AUC's and Cmax parameters.</non_inferiority_desc>
            <param_type>Ratio of the Geometric Mean</param_type>
            <param_value>101</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>91.9</ci_lower_limit>
            <ci_upper_limit>111</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-72 for Baseline Corrected Total Ursodiol</title>
        <description>Bioequivalence based on AUC0-72</description>
        <time_frame>Blood samples collected over 72 hour period</time_frame>
        <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodiol Tablets, 500 mg (test) dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Urso Forte™</title>
            <description>Urso Forte™ Tablets, 500 mg (reference) dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-72 for Baseline Corrected Total Ursodiol</title>
          <description>Bioequivalence based on AUC0-72</description>
          <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71039.735" spread="25782.013"/>
                    <measurement group_id="O2" value="68003.665" spread="27591.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of Variance (ANOVA) will be applied to log-transformed AUC's and Cmax parameters.</non_inferiority_desc>
            <param_type>Ratio of the Geometric Mean</param_type>
            <param_value>105</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>100</ci_lower_limit>
            <ci_upper_limit>111</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Unconjugated Ursodiol</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 72 hour period</time_frame>
        <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodiol Tablets, 500 mg (test) dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Urso Forte™</title>
            <description>Urso Forte™ Tablets, 500 mg (reference) dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Unconjugated Ursodiol</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4412.700" spread="1714.737"/>
                    <measurement group_id="O2" value="4475.406" spread="2066.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of Variance (ANOVA) will be applied to log-transformed AUC's and Cmax parameters.</non_inferiority_desc>
            <param_type>Ratio of the Mean</param_type>
            <param_value>101</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.5</ci_lower_limit>
            <ci_upper_limit>111</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-72 for Unconjugated Ursodiol</title>
        <description>Bioequivalence based on AUC0-72</description>
        <time_frame>Blood samples collected over 72 hour period</time_frame>
        <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodiol Tablets, 500 mg (test) dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Urso Forte™</title>
            <description>Urso Forte™ Tablets, 500 mg (reference) dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-72 for Unconjugated Ursodiol</title>
          <description>Bioequivalence based on AUC0-72</description>
          <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26739.080" spread="15149.751"/>
                    <measurement group_id="O2" value="24303.192" spread="11676.848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of Variance (ANOVA) will be applied to log-transformed AUC's and Cmax parameters.</non_inferiority_desc>
            <param_type>Ratio of the Mean</param_type>
            <param_value>110</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>103</ci_lower_limit>
            <ci_upper_limit>117</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Unconjugated Ursodiol - Baseline Corrected</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 72 hour period</time_frame>
        <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodiol Tablets, 500 mg (test) dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Urso Forte™</title>
            <description>Urso Forte™ Tablets, 500 mg (reference) dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Unconjugated Ursodiol - Baseline Corrected</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4384.711" spread="1716.444"/>
                    <measurement group_id="O2" value="4456.451" spread="2066.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of Variance (ANOVA) will be applied to log-transformed AUC's and Cmax parameters.</non_inferiority_desc>
            <param_type>Ratio of the Mean</param_type>
            <param_value>101</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>92.2</ci_lower_limit>
            <ci_upper_limit>111</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-72 for Unconjugated Ursodiol - Baseline Corrected</title>
        <description>Bioequivalence based on AUC0-72</description>
        <time_frame>Blood samples collected over 72 hour period</time_frame>
        <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ursodiol</title>
            <description>Ursodiol Tablets, 500 mg (test) dosed in either period.</description>
          </group>
          <group group_id="O2">
            <title>Urso Forte™</title>
            <description>Urso Forte™ Tablets, 500 mg (reference) dosed in either period.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-72 for Unconjugated Ursodiol - Baseline Corrected</title>
          <description>Bioequivalence based on AUC0-72</description>
          <population>Data from all subjects who completed the study was included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24795.871" spread="14561.991"/>
                    <measurement group_id="O2" value="22948.483" spread="10755.947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of Variance (ANOVA) will be applied to log-transformed AUC's and Cmax parameters.</non_inferiority_desc>
            <param_type>Ratio of the Mean</param_type>
            <param_value>107</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>100</ci_lower_limit>
            <ci_upper_limit>115</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>TEVA Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

